$NTLA
Intellia Therapeutics, Inc.

2016 Q4 Form 10-Q Financial Statement

#000119312516755383 Filed on November 01, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $5.630M $4.870M $1.690M
YoY Change 233.14% 188.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.120M $4.710M $1.530M
YoY Change 82.21% 207.84% 121.74%
% of Gross Profit
Research & Development $11.33M $7.861M $3.458M
YoY Change 158.99% 127.33% 1934.12%
% of Gross Profit
Depreciation & Amortization $400.0K $270.0K $100.0K
YoY Change 207.69% 170.0%
% of Gross Profit
Operating Expenses $11.33M $7.861M $3.458M
YoY Change 158.99% 127.33% 306.82%
Operating Profit -$10.82M -$7.697M -$3.301M
YoY Change 97.09% 133.17%
Interest Expense $260.0K $220.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$10.56M -$7.482M -$3.301M
YoY Change 92.37% 126.66% -52.23%
Income Tax $0.00 $0.00 -$282.0K
% Of Pretax Income
Net Earnings -$10.56M -$7.482M -$3.019M
YoY Change 101.39% 147.83% -56.31%
Net Earnings / Revenue -187.62% -153.63% -178.64%
Basic Earnings Per Share
Diluted Earnings Per Share -$305.3K -$217.9K -$86.04K
COMMON SHARES
Basic Shares Outstanding 36.00M shares 36.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $273.1M $290.6M $82.60M
YoY Change 260.29% 251.82%
Cash & Equivalents $273.1M $290.6M $82.61M
Short-Term Investments
Other Short-Term Assets $1.800M $1.000M $600.0K
YoY Change 125.0% 66.67%
Inventory
Prepaid Expenses
Receivables $6.454M $1.112M $1.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $281.3M $292.7M $84.30M
YoY Change 262.39% 247.21%
LONG-TERM ASSETS
Property, Plant & Equipment $10.63M $5.492M $2.000M
YoY Change 292.47% 174.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.035M $3.275M $1.500M
YoY Change 289.75% 118.33%
Total Long-Term Assets $17.66M $8.767M $3.400M
YoY Change 291.38% 157.85%
TOTAL ASSETS
Total Short-Term Assets $281.3M $292.7M $84.30M
Total Long-Term Assets $17.66M $8.767M $3.400M
Total Assets $299.0M $301.5M $87.70M
YoY Change 263.98% 243.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.652M $657.0K $700.0K
YoY Change 242.06% -6.14%
Accrued Expenses $5.900M $4.810M $3.300M
YoY Change 111.62% 45.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.73M $22.63M $10.40M
YoY Change 187.33% 117.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $293.0K $306.0K $5.100M
YoY Change -9.29% -94.0%
Total Long-Term Liabilities $293.0K $306.0K $5.100M
YoY Change -9.29% -94.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.73M $22.63M $10.40M
Total Long-Term Liabilities $293.0K $306.0K $5.100M
Total Liabilities $31.02M $22.94M $15.40M
YoY Change 181.57% 48.95%
SHAREHOLDERS EQUITY
Retained Earnings -$53.57M -$43.01M
YoY Change 144.21%
Common Stock $263.4M $261.1M
YoY Change 35737.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $209.8M $218.1M $72.30M
YoY Change
Total Liabilities & Shareholders Equity $299.0M $301.5M $87.70M
YoY Change 263.98% 243.75%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$10.56M -$7.482M -$3.019M
YoY Change 101.39% 147.83% -56.31%
Depreciation, Depletion And Amortization $400.0K $270.0K $100.0K
YoY Change 207.69% 170.0%
Cash From Operating Activities -$14.41M -$7.610M -$3.270M
YoY Change 162.48% 132.72% 336.0%
INVESTING ACTIVITIES
Capital Expenditures -$3.410M -$600.0K -$610.0K
YoY Change 305.95% -1.64%
Acquisitions
YoY Change
Other Investing Activities $0.00 $600.0K
YoY Change -600.0%
Cash From Investing Activities -$3.410M -$600.0K -$10.00K
YoY Change 305.95% 5900.0% -91.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 260.0K -1.860M 66.11M
YoY Change -157.78% -102.81% 663.39%
NET CHANGE
Cash From Operating Activities -14.41M -7.610M -3.270M
Cash From Investing Activities -3.410M -600.0K -10.00K
Cash From Financing Activities 260.0K -1.860M 66.11M
Net Change In Cash -17.56M -10.07M 62.83M
YoY Change 159.0% -116.03% 706.55%
FREE CASH FLOW
Cash From Operating Activities -$14.41M -$7.610M -$3.270M
Capital Expenditures -$3.410M -$600.0K -$610.0K
Free Cash Flow -$11.00M -$7.010M -$2.660M
YoY Change 136.56% 163.53% 254.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
200000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82612000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1874000
CY2016Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
270266000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
270266000
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35995074 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35995074 shares
CY2016Q3 us-gaap Assets
Assets
301469000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
292702000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
5600000
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
261127000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
290618000
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1112000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
60406000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
657000
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
17166000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2936000
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4810000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
32982000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4890000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4748000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
301469000
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
306000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
22633000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
9369000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
4891000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4609000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3275000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
26959000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4475000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5492000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.81
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
218124000
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15400000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.35
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
71613 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1550756 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.80
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43007000
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
972000
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
803000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3029000 shares
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35995331 shares
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9845000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1281000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
30000000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
30000000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2558755 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2558755 shares
CY2015Q4 us-gaap Assets
Assets
82139000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
77626000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
735000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75816000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3765000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1360000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6547000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
907000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2788000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82139000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
323000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10695000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1805000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2708000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-21201000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.04
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2227276 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.81
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
88557000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21936000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
810000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
456374 shares
CY2015Q4 ntla Remaining Obligation Acquired In Process Research And Development
RemainingObligationAcquiredInProcessResearchAndDevelopment
600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25875000 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
72767000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-48.65
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
144000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5474000
us-gaap Depreciation
Depreciation
196000
us-gaap Costs And Expenses
CostsAndExpenses
12269000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
900000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1220000
us-gaap Net Income Loss
NetIncomeLoss
-7152000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
74661000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7918000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1705000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
4351000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
405000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
360000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
841000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7918000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
170000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
70744000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000
us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-766000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10004000
us-gaap Income Tax Effects Allocated Directly To Equity
IncomeTaxEffectsAllocatedDirectlyToEquity
1000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-766000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
3728000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1705000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6795000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.794 pure
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
395000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.014 pure
us-gaap Share Based Compensation
ShareBasedCompensation
845000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
147000 shares
ntla Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
792000
ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
2622000
ntla Collaboration Consideration Allocated To Equity
CollaborationConsiderationAllocatedToEquity
2600000
ntla In Process Research And Development Acquired But Not Yet Paid
InProcessResearchAndDevelopmentAcquiredButNotYetPaid
800000
dei Entity Registrant Name
EntityRegistrantName
INTELLIA THERAPEUTICS, INC.
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4580000 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001652130
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4700000
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
214802000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
944000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11680000
us-gaap Depreciation
Depreciation
699000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Costs And Expenses
CostsAndExpenses
32189000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Investment Income Interest
InvestmentIncomeInterest
266000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
50519000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2760000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
170507000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
600000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1741000
us-gaap Net Income Loss
NetIncomeLoss
-21071000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21071000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2760000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
112000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
10852000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
154000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
162000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2675000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21337000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-17000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
167043000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
67260000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.34
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3365000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3301000
CY2015Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1688000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
675329 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1191 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.83
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
167139000
dei Trading Symbol
TradingSymbol
NTLA
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20509000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.880 pure
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2764000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2579707 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7081 shares
us-gaap Share Based Compensation
ShareBasedCompensation
4700000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18098000 shares
ntla Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
-88557000
ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
100000
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25875000 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.27
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1531000
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
4989000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-3019000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3301000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-282000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3458000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.97
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
579000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
294000 shares
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4580000 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4705000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
12566000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-7482000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7482000
CY2016Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
4869000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7697000
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
215000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7861000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.91
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2055000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34316000 shares

Files In Submission

Name View Source Status
0001193125-16-755383-index-headers.html Edgar Link pending
0001193125-16-755383-index.html Edgar Link pending
0001193125-16-755383.txt Edgar Link pending
0001193125-16-755383-xbrl.zip Edgar Link pending
d271640d10q.htm Edgar Link pending
d271640dex311.htm Edgar Link pending
d271640dex312.htm Edgar Link pending
d271640dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g271640g72x53.jpg Edgar Link pending
ntla-20160930.xml Edgar Link completed
ntla-20160930.xsd Edgar Link pending
ntla-20160930_cal.xml Edgar Link unprocessable
ntla-20160930_def.xml Edgar Link unprocessable
ntla-20160930_lab.xml Edgar Link unprocessable
ntla-20160930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending